24/7 Market News Snapshot 15 July, 2025 – bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF)

July 15, 2025

DENVER, Colo., 15 July, 2025 (www.247marketnews.com) – (NASDAQ:BIAF) are discussed in this article.
bioAffinity Technologies, Inc. (BIAF) is currently trading at $0.296, marking a 3.21% decrease from its opening price of $0.343. The stock’s decline follows a previous session closing price of $0.287, indicating a potential bearish trend. With a trading volume of 14.83 million shares, there appears to be heightened market activity, which may suggest investor interest or volatility in the stock’s performance. Analysts are closely monitoring the resistance level around $0.343 and the support level near $0.287 for any signals of reversal or continued decline.

In conjunction with this market activity, bioAffinity Technologies has announced a significant milestone in its mission to enhance early-stage lung cancer diagnostics. The company recently received notification of patent allowance from the China National Intellectual Property Administration (CNIPA) for innovative methods that leverage advanced flow cytometry techniques to predict lung cancer risk.

Maria Zannes, President and CEO of bioAffinity Technologies, emphasized the importance of this development: “As lung cancer continues to be a pressing health issue worldwide, particularly in China, securing this intellectual property not only enhances our competitive position but also opens doors to a crucial market that remains largely underserved.” This patent safeguards methods that utilize specific antibodies and the porphyrin TCPP to accurately identify cancer cell populations in sputum samples, directly supporting the company’s flagship product, CyPath® Lung.

CyPath® Lung has shown promising clinical outcomes, with a high sensitivity of 92%, specificity of 87%, and an accuracy of 88% in high-risk patients with small lung nodules. With China’s smoking population exceeding 300 million and approximately 1.06 million new lung cancer cases diagnosed annually, the need for effective early-stage diagnostics is critical. The patent further strengthens bioAffinity’s international portfolio, positioning the company as a leader in innovative diagnostic solutions while underscoring its commitment to developing technologies that address the global lung cancer crisis.

Related news for (BIAF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.